Table 1.
Phased ipilimumab | Concurrent ipilimumab | Chemotherapy control | |
---|---|---|---|
Median time to immune-related progression | 5.7 months | 5.5 months | 4.6 months |
HR and P value versus control | HR = 0.72, 0.05 | HR = 0.81, 0.13 | |
Median progression-free survival (WHO criteria) | 5.1 months | 4.1 months | 4.2 months |
HR and P value versus control | HR = 0.69, 0.02 | HR = 0.88, 0.25 | |
OS, median | 12.2 months | 9.7 months | 8.3 months |
P value versus control | HR = 0.87, 0.23 | HR = 0.99, 0.48 | |
OS at 1 year | 50 % | 42 % | 39 % |
HR hazard ratio, OS overall survival, WHO World Health Organization